Public biotech data assets Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
13:00
Aug 19
Aug 19
Public biotech data assets undervalued
A subset of public biotech companies sit on undervalued data assets that can be monetized sooner and at larger scale than analysts appreciate. There is also a long tail of uncovered, left-for-dead small caps that could become valuable as experimentation and biomanufacturing reaccelerate; he avoids single-asset clinical-trial trading.
HIGH
About Public biotech data assets Investor Commentary
Across the available history and selected sources, Buzzberg tracks Public biotech data assets across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Michael Dempsey.